NCT04477343View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

June 1, 2026

Study Completion Date

December 31, 2026

Conditions
Pancreatic Ductal AdenocarcinomaPancreatic Cancer
Interventions
DRUG

SX-682

Allosteric inhibitor to human CXCR1 and CXCR2 receptor

DRUG

Nivolumab Injectable Product

humanized monoclonal antibody to program cell death receptor 1 (PD1)

Trial Locations (1)

14642

RECRUITING

University of Rochester, Rochester

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Syntrix Biosystems, Inc.

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of Rochester

OTHER

NCT04477343 - A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Biotech Hunter | Biotech Hunter